Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTANASDAQ:LRMRNASDAQ:VACCNASDAQ:VTYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$7.18+1.0%$5.45$4.09▼$17.24$153.64M0.81285,338 shs62,975 shsLRMRLarimar Therapeutics$2.47+0.6%$2.10$1.61▼$11.20$157.83M0.79780,521 shs678,027 shsVACCVaccitech$1.01-6.5%$1.57$1.64▼$5.10$38.93M-0.4244,643 shs19,141 shsVTYXVentyx Biosciences$2.24+12.4%$1.28$0.78▼$5.66$159.69M0.851.37 million shs2.55 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals-1.11%+21.12%+30.70%-0.97%-41.91%LRMRLarimar Therapeutics+1.66%+23.12%-8.92%-19.93%-74.24%VACCVaccitech+0.93%+30.12%+18.42%+12.50%-46.00%VTYXVentyx Biosciences0.00%+12.43%+44.20%+28.39%-59.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.9178 of 5 stars3.41.00.04.73.42.50.0LRMRLarimar Therapeutics1.9278 of 5 stars3.61.00.00.03.31.70.0VACCVaccitechN/AN/AN/AN/AN/AN/AN/AN/AVTYXVentyx Biosciences3.1607 of 5 stars3.43.00.00.04.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$18.00150.70% UpsideLRMRLarimar Therapeutics 3.11Buy$19.67697.84% UpsideVACCVaccitech 0.00N/AN/AN/AVTYXVentyx Biosciences 2.75Moderate Buy$10.00347.03% UpsideCurrent Analyst Ratings BreakdownLatest VACC, LRMR, VTYX, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.003/25/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00 ➝ $26.003/25/2025LRMRLarimar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/25/2025LRMRLarimar TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$64.46M2.38N/AN/A$5.24 per share1.37LRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/AVACCVaccitech$13.42M2.90$0.05 per share19.30$6.52 per share0.15VTYXVentyx BiosciencesN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/4/2025 (Estimated)LRMRLarimar Therapeutics-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%8/6/2025 (Estimated)VACCVaccitech$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/AVTYXVentyx Biosciences-$192.96M-$1.75N/AN/AN/AN/A-54.94%-50.01%8/14/2025 (Estimated)Latest VACC, LRMR, VTYX, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/8/2025Q1 2025VTYXVentyx Biosciences-$0.48-$0.39+$0.09-$0.39N/AN/A4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/AVACCVaccitechN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.475.47LRMRLarimar TherapeuticsN/A13.1013.10VACCVaccitechN/A15.2615.26VTYXVentyx BiosciencesN/A23.5223.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%LRMRLarimar Therapeutics91.92%VACCVaccitech26.13%VTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%LRMRLarimar Therapeutics4.50%VACCVaccitech6.00%VTYXVentyx Biosciences14.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.38 million18.37 millionOptionableLRMRLarimar Therapeutics3064.03 million61.57 millionOptionableVACCVaccitech3338.55 million36.23 millionNot OptionableVTYXVentyx Biosciences3071.16 million57.86 millionOptionableVACC, LRMR, VTYX, and ENTA HeadlinesRecent News About These CompaniesMillennium Management LLC Purchases 1,008,760 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)June 1, 2025 | marketbeat.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Shares Acquired by Two Sigma Advisers LPMay 31, 2025 | marketbeat.comWoodline Partners LP Purchases Shares of 213,240 Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 29, 2025 | marketbeat.comVentyx Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comBank of America Corp DE Has $9.36 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 26, 2025 | marketbeat.comPoint72 Asset Management L.P. Takes $3.90 Million Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 22, 2025 | marketbeat.comVestal Point Capital LP Acquires 275,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 21, 2025 | marketbeat.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Deerfield Management Company L.P. Series CMay 10, 2025 | marketbeat.comVentyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate ProgressMay 8, 2025 | globenewswire.comWhy Ventyx Biosciences, Inc.’s (VTYX) Stock Is Down 6.88%May 7, 2025 | aaii.comSusquehanna Fundamental Investments LLC Buys Shares of 198,947 Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 6, 2025 | marketbeat.comGreat week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous yearMay 4, 2025 | finance.yahoo.comVentyx Biosciences announces seven additional appointments to SABApril 2, 2025 | markets.businessinsider.comVentyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease SpecialistsApril 1, 2025 | globenewswire.comVentyx Biosciences Reports 2024 Financial Results and ProgressMarch 4, 2025 | tipranks.comVentyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory ChallengesMarch 1, 2025 | tipranks.comH.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)February 28, 2025 | markets.businessinsider.comVentyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate ProgressFebruary 27, 2025 | globenewswire.comVentyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025February 18, 2025 | markets.businessinsider.comVentyx Biosciences’ VTX958 shows efficacy in Crohn’s DiseaseFebruary 18, 2025 | markets.businessinsider.comVentyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025February 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVACC, LRMR, VTYX, and ENTA Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$7.18 +0.07 (+0.98%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Larimar Therapeutics NASDAQ:LRMR$2.46 +0.02 (+0.61%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Vaccitech NASDAQ:VACCVaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Ventyx Biosciences NASDAQ:VTYX$2.24 +0.25 (+12.41%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
